Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Steven P. Treon, Andrew R. Branagan, Leukothea Ioakimidis, Jacob D. Soumerai, Christopher J. Patterson, Barry Turnbull, Parveen Wasi, Christos Emmanouilides, Stanley R. Frankel, Andrew Lister, Pierre Morel, Jeffrey Matous, Stephanie A. Gregory, Eva Kimby

Blood (2009) 113 (16): 3673–3678.

https://doi.org/10.1182/blood-2008-09-177329

Published: 2009

Journal Articles

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Steven Treon, MD, PhD, Andrew Branagan, Leukothea Ioakimidis, PhD, Jacob Soumerai, Christopher Patterson, MD, Parveen Wasi, MD, FRCP(C), Christos Emmanouilides, MD, PhD, Stanley R. Frankel, MD, T. Andrew Lister, MD, Pierre Morel, MD, Jeffrey Matous, MD, Stephanie A. Gregory, MD, Eva K. Kimby, MD, PhD

Blood (2008) 112 (11): 3057.

https://doi.org/10.1182/blood.V112.11.3057.3057

Published: 2008

Journal Articles

Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin’s Lymphoma (NHL).

John P. Leonard, MD, Stephen J. Schuster, MD, Christos Emmanouilides, MD, Felix Couture, MD, Nick Teoh, PhD, William A. Wegener, MD, PhD, David M. Goldenberg, ScD, MD

Blood (2007) 110 (11): 3419.

https://doi.org/10.1182/blood.V110.11.3419.3419

Published: 2007

Journal Articles

Analysis of the Incidence of Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Registration and Compassionate-Use Trials of Ibritumomab Tiuxetan Radioimmunotherapy (RIT).

Myron S. Czuczman, MD, Christos Emmanouilides, Mohamed Darif, Thomas E. Witzig, Leo I. Gordon, Steven Revell, Katie Vo, Arturo Molina

Blood (2006) 108 (11): 485.

https://doi.org/10.1182/blood.V108.11.485.485

Published: 2006

Journal Articles

Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT).

Ricardo Spielberger, MD, Christos Emmanouilides, MD, William Bensinger, MD, Alan Rong, PhD, Alessandra Cesano, MD, Patrick Stiff, MD

Blood (2005) 106 (11): 2925.

https://doi.org/10.1182/blood.V106.11.2925.2925

Published: 2005

Journal Articles

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Russell J. Schilder, MD, Thomas E. Witzig, MD, Ian Flinn, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Hua Wang, MS, Katie Vo, Arturo Molina, MD.

Blood (2004) 104 (11): 2629.

https://doi.org/10.1182/blood.V104.11.2629.2629

Published: 2004

Journal Articles

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Gregory Wiseman, MD, Peter Conti, MD, Katie Vo, Russell J. Schilder, MD, Paul Foster, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Dan Silverman, MD, Thomas E. Witzig, MD, Arturo Molina, MD

Blood (2004) 104 (11): 2634.

https://doi.org/10.1182/blood.V104.11.2634.2634

Published: 2004

Journal Articles

Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation.

Sergio Giralt, Brent Logan, Mei-Jei Zhang, Olivia McGaha, Karen Ballen, Christos Emmanouilides, Rajneesh Nath, Pablo Miguel Parker, David Porter, Brenda Sandmaier, Edmund Waller, Juliet Barker, Steven Pavletic, Daniel Weisdorf

Blood (2004) 104 (11): 2751.

https://doi.org/10.1182/blood.V104.11.2751.2751

Published: 2004

Journal Articles

Prior Autologous Hematopoietic Cell Transplantation Confers an Adverse Prognosis for Recipients of Allogeneic Transplantation Following Nonmyeloablative Preparative Conditioning.

Gary J. Schiller, M.D., Christos Emmanouilides, M.D., Ron Paquette, M.D., Peter Rosen, M.D., Jennifer Gansert, M.D., Ph.D., Mary C. Territo, M.D.

Blood (2004) 104 (11): 5054.

https://doi.org/10.1182/blood.V104.11.5054.5054

Published: 2004

Journal Articles

Pharmacokinetics of Ganciclovir Following Oral Valganciclovir Versus Intravenous Ganciclovir in Allogeneic Hematopoietic Stem-Cell Transplant Patients with Stable Graft-Versus-Host Disease of the Gastrointestinal Tract.

Drew J. Winston, M.D., Voravit Ratanatharathorn, M.D., Lindsey Baden, M.D., Christos Emmanouilides, M.D., Don Gabriel, M.D., Sherry Li, W. Robert Lange, M.D.

Blood (2004) 104 (11): 2223.

https://doi.org/10.1182/blood.V104.11.2223.2223

Published: 2004

Journal Articles

Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment

Drew J. Winston, Christos Emmanouilides, Kathy Bartoni, Gary J. Schiller, Ronald Paquette, Mary C. Territo

Blood (2004) 104 (5): 1581–1582.

https://doi.org/10.1182/blood-2004-03-1025

Published: 2004

Journal Articles

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 + B-cell lymphoma: long-term follow-up of a phase 1/2 study

Leo I. Gordon, Arturo Molina, Thomas Witzig, Christos Emmanouilides, Andrew Raubtischek, Mohamed Darif, Russell J. Schilder, Greg Wiseman, Christine A. White

Blood (2004) 103 (12): 4429–4431.

https://doi.org/10.1182/blood-2003-11-3883

Published: 2004

NARROW

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin’s Lymphoma (NHL).

Analysis of the Incidence of Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Registration and Compassionate-Use Trials of Ibritumomab Tiuxetan Radioimmunotherapy (RIT).

Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT).

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation.

Prior Autologous Hematopoietic Cell Transplantation Confers an Adverse Prognosis for Recipients of Allogeneic Transplantation Following Nonmyeloablative Preparative Conditioning.

Pharmacokinetics of Ganciclovir Following Oral Valganciclovir Versus Intravenous Ganciclovir in Allogeneic Hematopoietic Stem-Cell Transplant Patients with Stable Graft-Versus-Host Disease of the Gastrointestinal Tract.

Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 + B-cell lymphoma: long-term follow-up of a phase 1/2 study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only